- Global Pharma News & Resources

Global Mycoplasma Testing Market size to touch US$ 1.1 Bn by 2025 at a CAGR of 11%

Noida,Uttar Pradesh, India,Mar 04 2021 (WiredRelease) Report Ocean Pvt Ltd–:Global Mycoplasma Testing Market is estimated to see healthy growth, pegged at a CAGR of ~11% during the forecast period 2020-2025. The rapid growth in the R&D activities investments has massively contributed to the global market growth. Besides, the rising introduction of novel technologies by key players is expected to boost growth further. The increase in cell culture contamination is also another factor driving the change.

Get more information:

Due to the cultural method’s limitation, global researchers are involved in identifying and developing more accurate and rapid responsive mycoplasma tests in the past years. Such rapid tests’ primary advantages would be high sensitivity, the capability to identify a wide range of mycoplasma species, and cycle time reduction, thus dipping the overall production time. These rapid methods would also facilitate faster decision-making to minimize the risk of contamination spread. One such instance of an alternative method for culture-based testing is Nucleic Acid-based Technology (NAT), which permits rapid detection of mycoplasma in cell culture. In 2018, American Type Culture Collection announced its new Polymerase Chain Reaction (PCR) launch-based service to sense contaminants in mycoplasma cell cultures.

Various government authorities increasingly support research activities in the pharmaceutical and biotechnology sectors. For instance, the US government provides financial support to the global pharmaceutical companies to facilitate research-based activities for new drug development. In April 2019, the US Food and Drug Administration (FDA) declared its plan to amend the regulations about the only testing method used to detect mycoplasma. According to the FDA, the regulation is preventive and thus, prevents the use of other testing methods which may have the potential to detect mycoplasma accurately. Such biologics regulation changes are expected to improve specificity and sensitivity in mycoplasma detection tests, which further assist in evolving new technologies for the market consumers. Thus, an increase in government pharmaceutical and biotechnology research funding has stimulated R&D activities, thereby fostering mycoplasma testing products’ colossal application.

Considering the current growth trend, human mycoplasma is a crucial source of cell culture contamination due to laboratory technicians infected with M. orale or M. fermentans. Hence, testing of such bacteria is considered an essential requirement to generate robust data in biomedical research.

Segmentation Overview of the Global Mycoplasma Testing Market

The mycoplasma testing market has been segmented into Type, Antibacterial Drug Class, Route of Administration, and Distribution Channel. These major market segments are further categorized into various sub-segments to study the market in detail.

By Mycoplasma Testing Product Outlook
Kits & Reagents (PCR Assays, Nucleic Acid Detection Kits, Stains, Elimination Kits, Standards & Controls, Others)

By Mycoplasma Testing Technology Outlook (PCR, ELISA, Direct Assay, Indirect Assay, Microbial Culture Techniques, Enzymatic Methods)

By Mycoplasma Testing Application Outlook (Cell Line Testing, Virus Testing, End of Production Cells Testing, Others)

By Mycoplasma Testing End-use Outlook (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others)

Key Players Insights

TBionique Testing Laboratories, Inc., Merck KGaA, PromoCell GmbH, Lonza Group Ltd., ATCC (American Type Culture Collection), Biological Industries Israel Beit Haemek Ltd., Thermo Fisher Scientific, Charles River Laboratories International, Inc., and InvivoGen., among others, are the essential players considered in the global mycoplasma testing market research study.

For Purchase Enquiry at

This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 04-Mar-2021